Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.03 AUD
Change Today +0.001 / 4.17%
Volume 2.2M
PRR On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
NASDAQ GM
Xetra
As of 1:57 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

prima biomed ltd (PRR) Snapshot

Open
A$0.02
Previous Close
A$0.02
Day High
A$0.03
Day Low
A$0.02
52 Week High
05/29/14 - A$0.06
52 Week Low
04/17/15 - A$0.02
Market Cap
34.7M
Average Volume 10 Days
2.0M
EPS TTM
A$-0.01
Shares Outstanding
1.4B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRIMA BIOMED LTD (PRR)

Related News

No related news articles were found.

prima biomed ltd (PRR) Related Businessweek News

No Related Businessweek News Found

prima biomed ltd (PRR) Details

Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product currently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.

31 Employees
Last Reported Date: 08/27/14

prima biomed ltd (PRR) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: A$250.2K
Chief Technical Officer
Total Annual Compensation: A$325.6K
General Counsel and Company Secretary
Total Annual Compensation: A$160.0K
Compensation as of Fiscal Year 2014.

prima biomed ltd (PRR) Key Developments

Prima Biomed Ltd. Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Prima Biomed Ltd. reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported loss before income tax of AUD 6,401,086 against AUD 5,920,756 for the same period a year ago. Loss attributable to owners of the company was AUD 6,401,086 or 0.51 cents per basic and diluted share against AUD 5,956,531 or 0.49 cents per basic and diluted share for the same period a year ago. Net cash flows used in operating activities were AUD 6,678,881 against AUD 8,301,296 for the same period a year ago. Payment for purchases of plant and equipment was AUD 46,848 against AUD 52,505 for the same period a year ago. During the half year ended December 31, 2014, the company incurred an operating loss after tax of AUD 6,401,086.

Prima Biomed Ltd. Presents at 27th Annual ROTH Conference, Mar-10-2015 12:30 PM

Prima Biomed Ltd. Presents at 27th Annual ROTH Conference, Mar-10-2015 12:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States.

Prima Biomed Ltd. Presents at BIO-Europe Spring 2015, Mar-09-2015

Prima Biomed Ltd. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRR:AU A$0.03 AUD +0.001

PRR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRR.
View Industry Companies
 

Industry Analysis

PRR

Industry Average

Valuation PRR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.6x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit www.primabiomed.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.